The human cytomegalovirus IE1 protein: Past and present developments

Future Virology

Volumn 9, Issue 4, 2014, Pages 415-430

  Scherer, Myriam ^a   Stamminger, Thomas ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

cytomegalovirus; IE1; immediate early; intrinsic immunity; ND10; PML bodies; STAT factors; transactivation

Indexed keywords

IMMEDIATE EARLY PROTEIN;

CYTOMEGALOVIRUS INFECTION; HOST RESISTANCE; HUMAN; HUMAN CYTOMEGALOVIRUS; INNATE IMMUNITY; NONHUMAN; PERSISTENT VIRUS INFECTION; PRIMARY INFECTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; REVIEW;

EID: 84899996201     PISSN: 17460794     EISSN: 17460808     Source Type: Journal    
DOI: 10.2217/fvl.14.20     Document Type: Review

References (117)

1. Noriega V, Redmann V, Gardner T, Tortorella D. Diverse immune evasion strategies by human cytomegalovirus. Immunol. Res. 54(1-3), 140-151 (2012).
2. Goodrum F, Caviness K, Zagallo P. Human cytomegalovirus persistence. Cell Microbiol. 14(5), 644-655 (2012).
3. Stern-Ginossar N, Weisburd B, Michalski A et al. Decoding human cytomegalovirus. Science 338(6110), 1088-1093 (2012).
4. Wathen MW, Stinski MF. Temporal patterns of human cytomegalovirus transcription: mapping the viral RNAs synthesized at immediate early, early, and late times after infection. J. Virol. 41(2), 462-477 (1982).
5. McDonough SH, Spector DH. Transcription in human fibroblasts permissively infected by human cytomegalovirus strain AD169. Virology 125(1), 31-46 (1983).
6. Mocarski ES, Shenk T, Pass RF. Cytomegaloviruses. In: Fields Virology. Knipe DM, Howley PM (Eds). Lippincott Williams and Wilkins, PA, USA, 2701-2772 (2007).
7. Reddehase MJ. Antigens and immunoevasins: opponents in cytomegalovirus immune surveillance. Nat. Rev. Immunol. 2(11), 831-844 (2002).
8. Lilja AE, Mason PW. The next generation recombinant human cytomegalovirus vaccine candidates - beyond gB. Vaccine 30(49), 6980-6990 (2012).
9. Stenberg RM, Thomsen DR, Stinski MF. Structural analysis of the major immediate early gene of human cytomegalovirus. J. Virol. 49(1), 190-199 (1984).
10. Stenberg RM, Witte PR, Stinski MF. Multiple spliced and unspliced transcripts from human cytomegalovirus immediate- early region 2 and evidence for a common initiation site within immediate-early region 1. J. Virol. 56(3), 665-675 (1985).
11. Stenberg RM, Depto AS, Fortney J, Nelson JA. Regulated expression of early and late RNAs and proteins from the human cytomegalovirus immediate-early gene region. J. Virol. 63(6), 2699-2708 (1989).
12. Puchtler E, Stamminger T. An inducible promoter mediates abundant expression from the immediate-early 2 gene region of human cytomegalovirus at late times after infection. J. Virol. 65(11), 6301-6306 (1991).
13. Plachter B, Britt W, Vornhagen R, Stamminger T, Jahn G. Analysis of proteins encoded by IE regions 1 and 2 of human cytomegalovirus using monoclonal antibodies generated against recombinant antigens. Virology 193(2), 642-652 (1993).
14. Awasthi S, Isler JA, Alwine JC. Analysis of splice variants of the immediate-early 1 region of human cytomegalovirus. J. Virol. 78(15), 8191-8200 (2004).
15. Meier JL, Stinski MF. Regulation of human cytomegalovirus immediate-early gene expression. Intervirology 39(5-6), 331-342 (1996).
16. Boshart M, Weber F, Jahn G, Dorsch-Hasler K, Fleckenstein B, Schaffner W. A very strong enhancer is located upstream of an immediate early gene of human cytomegalovirus. Cell 41(2), 521-530 (1985).
17. Stamminger T, Fleckenstein B. Immediate- early transcription regulation of human cytomegalovirus. Curr. Top. Microbiol. Immunol. 154, 3-19 (1990).
18. Liu B, Stinski MF. Human cytomegalovirus contains a tegument protein that enhances transcription from promoters with upstream ATF and AP-1 cis -acting elements. J. Virol. 66(7), 4434-4444 (1992).
19. Winkler M, Schmolke S, Plachter B, Stamminger T. UL69 of HCMV, a homolog of the HSV ICP27, is contained within the tegument of virions and activates the major IE enhancer of HCMV in synergy with the tegument protein pp71(UL82). Scand. J. Infect. Dis. Suppl. 99, 8-9 (1995).
20. Stamminger T, Gstaiger M, Weinzierl K, Lorz K, Winkler M, Schaffner W. Open reading frame UL26 of human cytomegalovirus encodes a novel tegument protein that contains a strong transcriptional activation domain. J. Virol. 76(10), 4836-4847 (2002).
21. Schierling K, Stamminger T, Mertens T, Winkler M. Human cytomegalovirus tegument proteins ppUL82 (pp71) and ppUL35 interact and cooperatively activate the major immediate-early enhancer. J. Virol. 78(17), 9512-9523 (2004).
22. Sinclair J. Chromatin structure regulates human cytomegalovirus gene expression during latency, reactivation and lytic infection. Biochim. Biophys. Acta 1799(3-4), 286-295 (2010).
23. Greaves RF, Mocarski ES. Defective growth correlates with reduced accumulation of a viral DNA replication protein after low-multiplicity infection by a human cytomegalovirus IE1 mutant. J. Virol. 72(1), 366-379 (1998).
24. Gawn JM, Greaves RF. Absence of IE1 p72 protein function during low-multiplicity infection by human cytomegalovirus results in a broad block to viral delayed-early gene expression. J. Virol. 76(9), 4441-4455 (2002).
25. Zalckvar E, Paulus C, Tillo D et al. Nucleosome maps of the human cytomegalovirus genome reveal a temporal switch in chromatin organization linked to a major IE protein. Proc. Natl Acad. Sci. USA 110(32), 13126-13131 (2013).
26. Krauss S, Kaps J, Czech N, Paulus C, Nevels M. Physical requirements and functional consequences of complex formation between the cytomegalovirus IE1 protein and human STAT2. J. Virol. 83(24), 12854-12870 (2009).
27. Scherer M, Klingl S, Sevvana M et al. Insights into structural determinants for nuclear domain 10 disruption by the major immediate-early protein IE1 of human cytomegalovirus. Presented at: 38th Annual International Herpesvirus Workshop. Grand Rapids, MI, USA, 20-24 July 2013.
28. Wilkinson GW, Kelly C, Sinclair JH, Rickards C. Disruption of PML-associated nuclear bodies mediated by the human cytomegalovirus major immediate early gene product. J. Gen. Virol. 79(Pt 5), 1233-1245 (1998).
29. Lee HR, Huh YH, Kim YE, Lee K, Kim S, Ahn JH. N -terminal determinants of human cytomegalovirus IE1 protein in nuclear targeting and disrupting PML-associated subnuclear structures. Biochem. Biophys. Res. Commun. 356(2), 499-504 (2007).
30. Stenberg RM, Fortney J, Barlow SW, Magrane BP, Nelson JA, Ghazal P. Promoter-specific trans activation and repression by human cytomegalovirus immediate-early proteins involves common and unique protein domains. J. Virol. 64(4), 1556-1565 (1990).
31. Hayhurst GP, Bryant LA, Caswell RC, Walker SM, Sinclair JH. CCAAT Box-dependent activation of the TATA-less human DNA polymerase alpha promoter by the human cytomegalovirus 72-kilodalton major immediate-early protein. J. Virol. 69(1), 182-188 (1995).
32. Lee HR, Kim DJ, Lee JM et al. Ability of the human cytomegalovirus IE1 protein to modulate sumoylation of PML correlates with its functional activities in transcriptional regulation and infectivity in cultured fibroblast cells. J. Virol. 78(12), 6527-6542 (2004).
33. Ahn JH, Brignole EJ 3rd, Hayward GS. Disruption of PML subnuclear domains by the acidic IE1 protein of human cytomegalovirus is mediated through interaction with PML and may modulate a RING finger-dependent cryptic transactivator function of PML. Mol. Cell. Biol. 18(8), 4899-4913 (1998).
34. LaFemina RL, Pizzorno MC, Mosca JD, Hayward GS. Expression of the acidic nuclear immediate-early protein (IE1) of human cytomegalovirus in stable cell lines and its preferential association with metaphase chromosomes. Virology 172(2), 584-600 (1989).
35. Paulus C, Krauss S, Nevels M. A human cytomegalovirus antagonist of type I IFN-dependent signal transducer and activator of transcription signaling. Proc. Natl Acad. Sci. USA 103(10), 3840-3845 (2006).
36. Xu Y, Ahn JH, Cheng M et al. Proteasome-independent disruption of PML oncogenic domains (PODs), but not covalent modification by SUMO-1, is required for human cytomegalovirus immediate-early protein IE1 to inhibit PML-mediated transcriptional repression. J. Virol. 75(22), 10683-10695 (2001).
37. Reinhardt J, Smith GB, Himmelheber CT, Zizkhan-Clifford J, Mocarski ES. The carboxyl-terminal region of human cytomegalovirus IE1491aa contains an acidic domain that plays a regulatory role and a chromatin-tethering domain that is dispensable during viral replication. J. Virol. 79(1), 225-233 (2005).
38. Mucke K, Paulus C, Bernhardt K et al. Human cytomegalovirus major immediate- early 1 protein targets host chromosomes by docking to the acidic pocket on the nucleosome surface. J. Virol. 88(2), 1228-1248 (2013).
39. Huh YH, Kim YE, Kim ET et al. Binding STAT2 by the acidic domain of human cytomegalovirus IE1 promotes viral growth and is negatively regulated by SUMO. J. Virol. 82(21), 10444-10454 (2008).
40. Michelson-Fiske S, Horodniceanu F, Guillon JC. Immediate early antigens in human cytomegalovirus infected cells. Nature 270(5638), 615-617 (1977).
41. Marchini A, Liu H, Zhu H. Human cytomegalovirus with IE-2 (UL122) deleted fails to express early lytic genes. J. Virol. 75(4), 1870-1878 (2001).
42. Pizzorno MC, O'Hare P, Sha L, LaFemina RL, Hayward GS. Trans -activation and autoregulation of gene expression by the immediate-early region 2 gene products of human cytomegalovirus. J. Virol. 62(4), 1167-1179 (1988).
43. Hermiston TW, Malone CL, Witte PR, Stinski MF. Identification and characterization of the human cytomegalovirus immediate- early region 2 gene that stimulates gene expression from an inducible promoter. J. Virol. 61(10), 3214-3221 (1987).
44. Malone CL, Vesole DH, Stinski MF. Transactivation of a human cytomegalovirus early promoter by gene products from the immediate-early gene IE2 and augmentation by IE1: mutational analysis of the viral proteins. J. Virol. 64(4), 1498-1506 (1990).
45. Margolis MJ, Pajovic S, Wong EL et al. Interaction of the 72-kilodalton human cytomegalovirus IE1 gene product with E2F1 coincides with E2F-dependent activation of dihydrofolate reductase transcription. J. Virol. 69(12), 7759-7767 (1995).
46. Cherrington JM, Mocarski ES. Human cytomegalovirus IE1 transactivates the alpha promoter-enhancer via an 18-base-pair repeat element. J. Virol. 63(3), 1435-1440 (1989).
47. Lukac DM, Harel NY, Tanese N, Alwine JC. TAF-like functions of human cytomegalovirus immediate-early proteins. J. Virol. 71(10), 7227-7239 (1997).
48. Yurochko AD, Mayo MW, Poma EE, Baldwin AS Jr, Huang ES. Induction of the transcription factor Sp1 during human cytomegalovirus infection mediates upregulation of the p65 and p105/p50 NF-kappaB promoters. J. Virol. 71(6), 4638-4648 (1997).
49. Munch K, Messerle M, Plachter B, Koszinowski UH. An acidic region of the 89K murine cytomegalovirus immediate early protein interacts with DNA. J. Gen. Virol. 73(Pt 3), 499-506 (1992).
50. Poma EE, Kowalik TF, Zhu L, Sinclair JH, Huang ES. The human cytomegalovirus IE1-72 protein interacts with the cellular p107 protein and relieves p107-mediated transcriptional repression of an E2F-responsive promoter. J. Virol. 70(11), 7867-7877 (1996).
51. Nitzsche A, Paulus C, Nevels M. Temporal dynamics of cytomegalovirus chromatin assembly in productively infected human cells. J. Virol. 82(22), 11167-11180 (2008).
52. Nevels M, Paulus C, Shenk T. Human cytomegalovirus immediate-early 1 protein facilitates viral replication by antagonizing histone deacetylation. Proc. Natl Acad. Sci. USA 101(49), 17234-17239 (2004).
53. Wu WS, Vallian S, Seto E et al. The growth suppressor PML represses transcription by functionally and physically interacting with histone deacetylases. Mol. Cell. Biol. 21(7), 2259-2268 (2001).
54. Hollenbach AD, McPherson CJ, Mientjes EJ, Iyengar R, Grosveld G. Daxx and histone deacetylase II associate with chromatin through an interaction with core histones and the chromatin-associated protein Dek. J. Cell Sci. 115(Pt 16), 3319-3330 (2002).
55. Li H, Leo C, Zhu J et al. Sequestration and inhibition of Daxx-mediated transcriptional repression by PML. Mol. Cell. Biol. 20(5), 1784-1796 (2000).
56. Xue Y, Gibbons R, Yan Z et al. The ATRX syndrome protein forms a chromatin-remodeling complex with Daxx and localizes in promyelocytic leukemia nuclear bodies. Proc. Natl Acad. Sci. USA 100(19), 10635-10640 (2003).
57. Reeves M, Woodhall D, Compton T, Sinclair J. Human cytomegalovirus IE72 protein interacts with the transcriptional repressor hDaxx to regulate LUNA gene expression during lytic infection. J. Virol. 84(14), 7185-7194 (2010).
58. Bieniasz PD. Intrinsic immunity: a front-line defense against viral attack. Nat. Immunol. 5(11), 1109-1115 (2004).
59. Tavalai N, Stamminger T. New insights into the role of the subnuclear structure ND10 for viral infection. Biochim. Biophys. Acta 1783(11), 2207-2221 (2008).
60. Kamitani T, Kito K, Nguyen HP, Wada H, Fukuda-Kamitani T, Yeh ET. Identification of three major sentrinization sites in PML. J. Biol. Chem. 273(41), 26675-26682 (1998).
61. Shen TH, Lin HK, Scaglioni PP, Yung TM, Pandolfi PP. The mechanisms of PML-nuclear body formation. Mol. Cell 24(3), 331-339 (2006).
62. Zhong S, Muller S, Ronchetti S, Freemont PS, Dejean A, Pandolfi PP. Role of SUMO-1- modified PML in nuclear body formation. Blood 95(9), 2748-2753 (2000).
63. Ishov AM, Sotnikov AG, Negorev D et al. PML is critical for ND10 formation and recruits the PML-interacting protein Daxx to this nuclear structure when modified by SUMO-1. J. Cell Biol. 147(2), 221-233 (1999).
64. Tavalai N, Papior P, Rechter S, Leis M, Stamminger T. Evidence for a role of the cellular ND10 protein PML in mediating intrinsic immunity against human cytomegalovirus infections. J. Virol. 80(16), 8006-8018 (2006).
65. Tavalai N, Papior P, Rechter S, Stamminger T. Nuclear domain 10 components promyelocytic leukemia protein and hDaxx independently contribute to an intrinsic antiviral defense against human cytomegalovirus infection. J. Virol. 82(1), 126-137 (2008).
66. Adler M, Tavalai N, Muller R, Stamminger T. Human cytomegalovirus immediate-early gene expression is restricted by the nuclear domain 10 component Sp100. J. Gen. Virol. 92(Pt 7), 1532-1538 (2011).
67. Saffert RT, Kalejta RF. Inactivating a cellular intrinsic immune defense mediated by Daxx is the mechanism through which the human cytomegalovirus pp71 protein stimulates viral immediate-early gene expression. J. Virol. 80(8), 3863-3871 (2006).
68. Woodhall DL, Groves IJ, Reeves MB, Wilkinson G, Sinclair JH. Human Daxx-mediated repression of human cytomegalovirus gene expression correlates with a repressive chromatin structure around the major immediate early promoter. J. Biol. Chem. 281(49), 37652-37660 (2006).
69. Glass M, Everett RD. Components of promyelocytic leukemia nuclear bodies (ND10) act cooperatively to repress herpesvirus infection. J. Virol. 87(4), 2174-2185 (2013).
70. Tavalai N, Stamminger T. Intrinsic cellular defense mechanisms targeting human cytomegalovirus. Virus Res. 157(2), 128-133 (2011).
71. Lukashchuk V, McFarlane S, Everett RD, Preston CM. Human cytomegalovirus protein pp71 displaces the chromatin-associated factor ATRX from nuclear domain 10 at early stages of infection. J. Virol. 82(24), 12543-12554 (2008).
72. Ahn JH, Hayward GS. Disruption of PML-associated nuclear bodies by IE1 correlates with efficient early stages of viral gene expression and DNA replication in human cytomegalovirus infection. Virology 274(1), 39-55 (2000).
73. Korioth F, Maul GG, Plachter B, Stamminger T, Frey J. The nuclear domain 10 (ND10) is disrupted by the human cytomegalovirus gene product IE1. Exp. Cell Res. 229(1), 155-158 (1996).
74. Ahn JH, Hayward GS. The major immediate-early proteins IE1 and IE2 of human cytomegalovirus colocalize with and disrupt PML-associated nuclear bodies at very early times in infected permissive cells. J. Virol. 71(6), 4599-4613 (1997).
75. Jensen K, Shiels C, Freemont PS. PML protein isoforms and the RBCC/TRIM motif. Oncogene 20(49), 7223-7233 (2001).
76. Boutell C, Cuchet-Lourenco D, Vanni E et al. A viral ubiquitin ligase has substrate preferential SUMO targeted ubiquitin ligase activity that counteracts intrinsic antiviral defence. PLoS Pathog. 7(9), e1002245 (2011).
77. Marcos-Villar L, Lopitz-Otsoa F, Gallego P et al. Kaposi's sarcoma-associated herpesvirus protein LANA2 disrupts PML oncogenic domains and inhibits PML-mediated transcriptional repression of the survivin gene. J. Virol. 83(17), 8849-8858 (2009).
78. Wang L, Oliver SL, Sommer M, Rajamani J, Reichelt M, Arvin AM. Disruption of PML nuclear bodies is mediated by ORF61 SUMO-interacting motifs and required for varicella-zoster virus pathogenesis in skin. PLoS Pathog. 7(8), e1002157 (2011).
79. Kang H, Kim ET, Lee HR et al. Inhibition of SUMO-independent PML oligomerization by the human cytomegalovirus IE1 protein. J. Gen. Virol. 87(Pt 8), 2181-2190 (2006).
80. Muller S, Dejean A. Viral immediate-early proteins abrogate the modification by SUMO-1 of PML and Sp100 proteins, correlating with nuclear body disruption. J. Virol. 73(6), 5137-5143 (1999).
81. Tavalai N, Adler M, Scherer M, Riedl Y, Stamminger T. Evidence for a dual antiviral role of the major nuclear domain 10 component Sp100 during the immediate- early and late phases of the human cytomegalovirus replication cycle. J. Virol. 85(18), 9447-9458 (2011).
82. Kim YE, Lee JH, Kim ET et al. Human cytomegalovirus infection causes degradation of Sp100 proteins that suppress viral gene expression. J. Virol. 85(22), 11928-11937 (2011).
83. Negorev DG, Vladimirova OV, Maul GG. Differential functions of interferon-upregulated Sp100 isoforms: herpes simplex virus type 1 promoter-based immediate-early gene suppression and PML protection from ICP0-mediated degradation. J. Virol. 83(10), 5168-5180 (2009).
84. Negorev DG, Vladimirova OV, Kossenkov AV et al. Sp100 as a potent tumor suppressor: accelerated senescence and rapid malignant transformation of human fibroblasts through modulation of an embryonic stem cell program. Cancer Res. 70(23), 9991-10001 (2010).
85. Everett RD, Freemont P, Saitoh H et al. The disruption of ND10 during herpes simplex virus infection correlates with the Vmw110- and proteasome-dependent loss of several PML isoforms. J. Virol. 72(8), 6581-6591 (1998).
86. Everett RD, Parsy ML, Orr A. Analysis of the functions of herpes simplex virus type 1 regulatory protein ICP0 that are critical for lytic infection and derepression of quiescent viral genomes. J. Virol. 83(10), 4963-4977 (2009).
87. Hofmann H, Floss S, Stamminger T. Covalent modification of the transactivator protein IE2-p86 of human cytomegalovirus by conjugation to the ubiquitin-homologous proteins SUMO-1 and hSMT3b. J. Virol. 74(6), 2510-2524 (2000).
88. Sinigalia E, Alvisi G, Segre CV et al. The human cytomegalovirus DNA polymerase processivity factor UL44 is modified by SUMO in a DNA-dependent manner. PLoS ONE 7(11), e49630 (2012).
89. Berndt A, Hofmann-Winkler H, Tavalai N, Hahn G, Stamminger T. Importance of covalent and noncovalent SUMO interactions with the major human cytomegalovirus transactivator IE2p86 for viral infection. J. Virol. 83(24), 12881-12894 (2009).
90. Lee HR, Ahn JH. Sumoylation of the major immediate-early IE2 protein of human cytomegalovirus Towne strain is not required for virus growth in cultured human fibroblasts. J. Gen. Virol. 85(Pt 8), 2149-2154 (2004).
91. Scherer M, Reuter N, Wagenknecht N, Otto V, Sticht H, Stamminger T. Small ubiquitin-related modifier (SUMO) pathway-mediated enhancement of human cytomegalovirus replication correlates with a recruitment of SUMO-1/3 proteins to viral replication compartments. J. Gen. Virol. 94(Pt 6), 1373-1384 (2013).
92. Samuel CE. Antiviral actions of interferons. Clin. Microbiol. Rev. 14(4), 778-809 (2001).
93. Le VT, Trilling M, Wilborn M, Hengel H, Zimmermann A. Human cytomegalovirus interferes with signal transducer and activator of transcription (STAT) 2 protein stability and tyrosine phosphorylation. J. Gen. Virol. 89(Pt 10), 2416-2426 (2008).
94. Knoblach T, Grandel B, Seiler J, Nevels M, Paulus C. Human cytomegalovirus IE1 protein elicits a type II interferon-like host cell response that depends on activated STAT1 but not interferon-gamma. PLoS Pathog. 7(4), e1002016 (2011).
95. Reitsma JM, Sato H, Nevels M, Terhune SS, Paulus C. Human cytomegalovirus IE1 protein disrupts interleukin-6 signaling by sequestering STAT3 in the nucleus. J. Virol. 87(19), 10763-10776 (2013).
96. Jones SA. Directing transition from innate to acquired immunity: defining a role for IL-6. J. Immunol. 175(6), 3463-3468 (2005).
97. Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat. Rev. Cancer 9(11), 798-809 (2009).
98. Bromberg J, Darnell JE Jr. The role of STATs in transcriptional control and their impact on cellular function. Oncogene 19(21), 2468-2473 (2000).
99. Bresnahan WA, Boldogh I, Thompson EA, Albrecht T. Human cytomegalovirus inhibits cellular DNA synthesis and arrests productively infected cells in late G1. Virology 224(1), 150-160 (1996).
100. Dittmer D, Mocarski ES. Human cytomegalovirus infection inhibits G1/S transition. J. Virol. 71(2), 1629-1634 (1997).
101. Johnson RA, Yurochko AD, Poma EE, Zhu L, Huang ES. Domain mapping of the human cytomegalovirus IE1-72 and cellular p107 protein-protein interaction and the possible functional consequences. J. Gen. Virol. 80(Pt 5), 1293-1303 (1999).
102. Zhang Z, Huong SM, Wang X, Huang DY, Huang ES. Interactions between human cytomegalovirus IE1-72 and cellular p107: functional domains and mechanisms of up-regulation of cyclin E/cdk2 kinase activity. J. Virol. 77(23), 12660-12670 (2003).
103. Castillo JP, Yurochko AD, Kowalik TF. Role of human cytomegalovirus immediate-early proteins in cell growth control. J. Virol. 74(17), 8028-8037 (2000).
104. Castillo JP, Frame FM, Rogoff HA, Pickering MT, Yurochko AD, Kowalik TF. Human cytomegalovirus IE1-72 activates ataxia telangiectasia mutated kinase and a p53/ p21-mediated growth arrest response. J. Virol. 79(17), 11467-11475 (2005).
105. Casavant NC, Luo MH, Rosenke K, Winegardner T, Zurawska A, Fortunato EA. Potential role for p53 in the permissive life cycle of human cytomegalovirus. J. Virol. 80(17), 8390-8401 (2006).
106. Hwang ES, Zhang Z, Cai H et al. Human cytomegalovirus IE1-72 protein interacts with p53 and inhibits p53-dependent transactivation by a mechanism different from that of IE2-86 protein. J. Virol. 83(23), 12388-12398 (2009).
107. Pajovic S, Wong EL, Black AR, Azizkhan JC. Identification of a viral kinase that phosphorylates specific E2Fs and pocket proteins. Mol. Cell Biol. 17(11), 6459-6464 (1997).
108. E X, Pickering MT, Debatis M et al. An E2F1-mediated DNA damage response contributes to the replication of human cytomegalovirus. PLoS Pathog. 7(5), e1001342 (2011).
109. Zhu H, Shen Y, Shenk T. Human cytomegalovirus IE1 and IE2 proteins block apoptosis. J. Virol. 69(12), 7960-7970 (1995).
110. Yu Y, Alwine JC. Human cytomegalovirus major immediate-early proteins and simian virus 40 large T antigen can inhibit apoptosis through activation of the phosphatidylinositide 3?-OH kinase pathway and the cellular kinase Akt. J. Virol. 76(8), 3731-3738 (2002).
111. Kim J, Kwon YJ, Park ES et al. Human cytomegalovirus (HCMV) IE1 plays role in resistance to apoptosis with etoposide in cancer cell line by Cdk2 accumulation. Microbiol. Immunol. 47(12), 959-967 (2003).
112. Cobbs CS, Soroceanu L, Denham S, Zhang W, Kraus MH. Modulation of oncogenic phenotype in human glioma cells by cytomegalovirus IE1-mediated mitogenicity. Cancer Res. 68(3), 724-730 (2008).
113. Andoniou CE, Degli-Esposti MA. Insights into the mechanisms of CMV-mediated interference with cellular apoptosis. Immunol. Cell Biol. 84(1), 99-106 (2006).
114. Shin HJ, Kim YE, Kim ET, Ahn JH. The chromatin-tethering domain of human cytomegalovirus immediate-early (IE) 1 mediates associations of IE1, PML and STAT2 with mitotic chromosomes, but is not essential for viral replication. J. Gen. Virol. 93(Pt 4), 716-721 (2012).
115. Barbera AJ, Chodaparambil JV, Kelley- Clarke B et al. The nucleosomal surface as a docking station for Kaposi's sarcoma herpesvirus LANA. Science 311(5762), 856-861 (2006).
116. Ballestas ME, Chatis PA, Kaye KM. Efficient persistence of extrachromosomal KSHV DNA mediated by latency-associated nuclear antigen. Science 284(5414), 641-644 (1999).
117. Sinclair J. Human cytomegalovirus: latency and reactivation in the myeloid lineage. J. Clin. Virol. 41(3), 180-185 (2008).